Compare DNN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNN | NMRA |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 424.4M |
| IPO Year | 1997 | 2023 |
| Metric | DNN | NMRA |
|---|---|---|
| Price | $2.62 | $1.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 49.9M | 980.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,493,456.00 | N/A |
| Revenue This Year | $197.29 | N/A |
| Revenue Next Year | $55.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.35 | N/A |
| 52 Week Low | $1.08 | $0.61 |
| 52 Week High | $3.42 | $11.57 |
| Indicator | DNN | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 33.78 |
| Support Level | $2.60 | $2.05 |
| Resistance Level | $2.82 | $2.36 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 37.48 | 6.58 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.